Ascendis Pharma AS
$ 255.62
0.08%
10 Aug - close price
- Market Cap 16,753,065,000 USD
- Current Price $ 255.62
- High / Low $ 257.42 / 251.00
- Stock P/E 29.19
- Book Value 9.05
- EPS 8.75
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE 0.33 %
- 52 Week High 282.15
- 52 Week Low 186.05
About
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Analyst Target Price
$309.46
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-11 | 2025-11-12 | 2025-08-07 | 2025-05-01 | 2025-02-12 | 2024-11-14 | 2024-09-03 | 2024-05-02 | 2024-02-07 | 2023-11-07 | 2023-09-05 |
| Reported EPS | 0.27 | -0.55 | -1 | -0.93 | -1.58 | -0.64 | -1.72 | -2.11 | -2.3 | -1.54 | -2.88 | -2.16 |
| Estimated EPS | 0.43 | -0.24 | -0.12 | -1.42 | -1.51 | -1.17 | -1.46 | -1.46 | -1.42 | -1.76 | -2.25 | -2.59 |
| Surprise | -0.16 | -0.31 | -0.88 | 0.49 | -0.07 | 0.53 | -0.26 | -0.65 | -0.88 | 0.22 | -0.63 | 0.43 |
| Surprise Percentage | -37.2093% | -129.1667% | -733.3333% | 34.507% | -4.6358% | 45.2991% | -17.8082% | -44.5205% | -61.9718% | 12.5% | -28% | 16.6023% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ASND
2026-08-09 02:40:23
Evercore has reiterated its Buy rating for Ascendis Pharma A/S (ASND.US), maintaining a target price of $329. This indicates continued confidence in the company's financial prospects and stock performance by the investment firm.
2026-08-09 00:16:00
This article analyzes Ascendis Pharma A/s (NASDAQ: ASND), highlighting a mid-channel oscillation pattern and a strong 27.6:1 risk-reward setup. It provides institutional trading strategies for various risk profiles, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report identifies positive near-term sentiment with a weak mid-term bias within a long-term strength context.
2026-08-08 01:40:34
Cantor Fitzgerald has reiterated its Buy rating for Ascendis Pharma A/S (ASND.US) and maintained its target price at $300. This indicates the firm's continued confidence in the company's financial prospects and stock performance.
2026-08-07 02:40:24
Ascendis Pharma (ASND) has experienced a recent pullback, with its stock down about 9% over the past month. Despite this, a common valuation narrative suggests the company is 19.8% undervalued, with a fair value of $304.60 compared to its current share price of $244.20. The company's focus on long-acting therapies and its TransCon technology platform, particularly for achondroplasia, are highlighted as key drivers for potential future growth.
2026-08-07 00:11:17
Ascendis Pharma (Nasdaq: ASND) will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the U.S. market opens. The company will host a conference call and live webcast at 8:00 a.m. Eastern Time, with a 30-day replay available on its website. This announcement follows a historical trend where similar earnings-date announcements for Ascendis Pharma have preceded negative 24-hour share price reactions.
2026-08-06 23:40:34
Ascendis Pharma A/S announced it will report its second-quarter 2026 financial results and provide a business update on Thursday, August 13, 2026. The company will also host a conference call and live webcast to discuss these results. Ascendis Pharma focuses on developing therapies using its TransCon technology platform.
